Sulfanilamide

DERMATOLOGICALS

Key facts

Sulfanilamide is an ofm drug catalogued in DrugCentral. It was first approved by the FDA in 1965. DrugCentral lists 35 molecular targets, including CA13, Ca13 and CA12. Recorded indications include Candidal vulvovaginitis and Vulvovaginitis.

• Approval status: ofm (first approved 1965 by the FDA).
• Molecular targets: CA13, Ca13, CA12 and CA7 (35 listed in DrugCentral).
• Indications: Candidal vulvovaginitis and Vulvovaginitis.
• ATC code: D06BA05 (Sulfonamides).
• Molecular formula: C6H8N2O2S; molecular weight 172.20 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Candidal vulvovaginitis
• Vulvovaginitis

Contraindications (6)

• Anemia due to enzyme deficiency
• Deficiency of glucose-6-phosphate dehydrogenase
• Disease of blood AND/OR blood-forming organ
• Disease of liver
• Kidney disease
• Porphyria

Mechanism & targets

Molecular targets (35)

Target	Gene	Action	Activity
Carbonic anhydrase 13	CA13	unknown	Ki 7.49
Carbonic anhydrase 13	Ca13	unknown	Ki 7.49
Carbonic anhydrase 12	CA12	unknown	Ki 7.43
Carbonic anhydrase 7	CA7	unknown	Ki 7.15
Delta carbonic anhydrase	ca1	unknown	Ki 6.74
Carbonic anhydrase 2	CA2	unknown	Ki 6.62
Carbonic anhydrase 9	CA9	unknown	Ki 6.62
Carbonic anhydrase	NCE103	unknown	Ki 6.62
Carbonic anhydrase	—	unknown	Ki 6.60
Carbonic anhydrase 1	CA1	unknown	Ki 6.52
Carbonic anhydrase	CA2	unknown	Ki 6.52
Alpha carbonic anhydrase	CA	unknown	Ki 6.44
Carbonic anhydrase	cynT	unknown	Ki 6.37
Carbonic anhydrase, alpha family	—	unknown	Ki 6.20
Carbonate dehydratase	—	unknown	Ki 6.19
Carbonic anhydrase 2	CAN2	unknown	Ki 6.11
Carbonic anhydrase 2	CA2	unknown	Ki 6.07
Carbonic anhydrase	—	unknown	Ki 6.06
Carbonic anhydrase 6	CA6	unknown	Ki 6.03
Carbonic anhydrase 3	CA3	unknown	Ki 6.01

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1965-06-05	FDA	—	MEDA PHARMS

ATC classification

ATC code	Therapeutic hierarchy
D06BA05	DERMATOLOGICALS › ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE › CHEMOTHERAPEUTICS FOR TOPICAL USE › Sulfonamides
J01EB06	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › SULFONAMIDES AND TRIMETHOPRIM › Short-acting sulfonamides

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Drug hypersensitivity	205.3

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Sulfanilamide is on its molecule page.

• Molecular formula: C₆H₈N₂O₂S
• Molecular weight: 172.20 g/mol
• CAS number: 63-74-1
• InChIKey: FDDDEECHVMSUSB-UHFFFAOYSA-N
• PubChem CID: 5333

NC1=CC=C(C=C1)S(N)(=O)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Sulfanilamide used for?

DrugCentral lists the following indications for Sulfanilamide: Candidal vulvovaginitis and Vulvovaginitis.

How does Sulfanilamide work?

Its molecular targets in DrugCentral include CA13, Ca13, CA12 and CA7.

When was Sulfanilamide first approved?

Sulfanilamide was first approved by the FDA in 1965.

What is the chemical formula of Sulfanilamide?

Sulfanilamide has the molecular formula C6H8N2O2S and a molecular weight of 172.20 g/mol.

Sources

• DrugCentral drug card 2521 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL21 — compound record and bioactivity
• PubChem CID 5333 — chemical identifiers
• DrugBank DB00259 — drug record
• FDA UNII 21240MF57M — substance identity
• DailyMed: FDA labels for Sulfanilamide — current prescribing information (label search)
• UniProt Q8N1Q1 (CA13) — target protein
• UniProt O43570 (CA12) — target protein
• UniProt P43166 (CA7) — target protein
• UniProt P00918 (CA2) — target protein
• UniProt Q16790 (CA9) — target protein
• UniProt P00915 (CA1) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.